Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients.

Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. Abstract Text:

Ramon Kumar,Tobias T Lee,Allen Jeremias,Christopher P Ruisi,Brett Sylvia,Jorge Magallon,Ajay J Kirtane,Brian Bigelow,Martin Abrahamson,Duane S Pinto,Kalon K L Ho,David J Cohen,Joseph P Carrozza,Donald E Cutlip,Ramon Kumar,Tobias T Lee,Allen Jeremias,Christopher P Ruisi,Brett Sylvia,Jorge Magallon,Ajay J Kirtane,Brian Bigelow,Martin Abrahamson,Duane S Pinto,Kalon K L Ho,David J Cohen,Joseph P Carrozza,Donald E Cutlip,

The effect of insulin therapy on adverse cardiovascular outcomes in diabetic patients has been debated and a reduced benefit in clinical restenosis outcomes after sirolimus stenting has been reported among diabetic patients requiring insulin therapy. We analyzed 297 diabetic patients receiving sirolimus-eluting stents, including 115 (39%) on insulin therapy, and compared outcomes with 541 nondiabetic patients treated consecutively during the same interval. The rates of target lesion revascularization (9.5% vs 3.5%, p = 0.003) and cardiac death or myocardial infarction (MI, 7.1% vs 3.1%, p = 0.012) were significantly higher for diabetic patients. Insulin treatment was independently associated with increased risk for target lesion revascularization (odds ratio [OR] 2.48, 95% confidence interval [CI] 1.22 to 5.00) and cardiac death or MI (hazard ratio [HR] 2.85, 95% CI 1.41 to 5.77), whereas the adjusted risk for diabetic patients not treated with insulin was not significantly different from patients without diabetes for target lesion revascularization (OR 1.32, 95% CI 0.66 to 2.62) or cardiac death or MI (HR 1.04, 95% CI 0.50 to 2.17). In conclusion, diabetes mellitus is associated with increased risk for target lesion revascularization and cardiac death or MI after receiving sirolimus-eluting stenting, and is significantly exaggerated by the requirement for insulin therapy.

Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. Publishing Authors By Initials

R Kumar,TT Lee,A Jeremias,CP Ruisi,B Sylvia,J Magallon,AJ Kirtane,B Bigelow,M Abrahamson,DS Pinto,KK Ho,DJ Cohen,JP Carrozza,DE Cutlip,R Kumar,TT Lee,A Jeremias,CP Ruisi,B Sylvia,J Magallon,AJ Kirtane,B Bigelow,M Abrahamson,DS Pinto,KK Ho,DJ Cohen,JP Carrozza,DE Cutlip,

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: The American journal of cardiology

VOLUME: 100

Page Numbers: 1187-91

Journal Abbreviation: Am. J. Cardiol.

ISSN: 0002-9149

DAY: 2

MONTH: 08

YEAR: 2007

Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 207277

Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: administration & dosage

Chemical & Substance for Abstract: Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients. Information

Substance Name: Sirolimus

Registry Number: 53123-88-9

Grant and Affiliation Information for Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients.

AFFILIATION: Department of Medicine, Cardiology Division, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Am J Cardiol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients Related Publications

• Comparison of outcomes using sirolimus-eluting stenting in diabetic versus nondiabetic patients with comparison of insulin versus non-insulin therapy in the diabetic patients.
• Non-injurious Stretch-shortening Contractions: Age Effects on Muscle Physiology and Morphology: 1861: Board #149 10:30 AM - 10:30 AM.
• Relationship of chronic kidney disease to cardiovascular death and myocardial infarction following coronary stenting.
• Risk of target lesion revascularization after coronary stenting in patients with and without chronic kidney disease.